Fennec COO Adrian Haigh departs; 66,667 options accelerated at $8.03

FENNEC PHARMACEUTICALS INC.

Adrian Haigh left COO role effective June 30, 2024; joined as COO Aug 2023 after nine years as independent director.
Separation agreement accelerates vesting of options for 66,667 common shares at $8.03, expiring June 30, 2027.
Company actively searching for a U.S.-based leader to replace Haigh.
Haigh cited timing after Norgine licensing deal and U.S. commercial strategy refocus as reasons to step down.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Adrian Haigh

Chief Operating Officer

FENC · FENNEC PHARMACEUTICALS INC.

Effective: 2024-06-30
Filed: July 2, 2024, 7:59 PM ET

On June 30, 2024, Adrian Haigh departed from his position as Fennec Pharmaceuticals Inc.’s (the "Company") Chief Operating Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Adrian Haigh departed as Chief Operating Officer at FENNEC PHARMACEUTICALS INC..

Action: departed
Role: Chief Operating Officer

Exact text from the filing

On June 30, 2024, Adrian Haigh departed from his position as Fennec Pharmaceuticals Inc.’s (the "Company") Chief Operating Officer

View on SEC.gov

FENNEC PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-076936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.